| Literature DB >> 29511016 |
Pengli Jia1, Li Tang1, Jiajie Yu1, Andy H Lee2, Xu Zhou3, Deying Kang1, Yanan Luo4, Jiali Liu1, Xin Sun1.
Abstract
OBJECTIVE: To assess risk of bias and to investigate methodological issues concerning the design, conduct and analysis of randomised controlled trials (RCTs) testing acupuncture for knee osteoarthritis (KOA).Entities:
Keywords: acupuncture; knee osteoarthritis; methodological characteristics; quality; trial design
Mesh:
Year: 2018 PMID: 29511016 PMCID: PMC5855180 DOI: 10.1136/bmjopen-2017-019847
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart for search and selection processes.
General characteristics of included trials
| Features of included RCTs | Total | Chinese | English |
| No. of authors (median (IQR)) | 3 (2–5) | 5 (4–7.5) | 3 (1–4) |
| Sample size (median (IQR)) | 76 (60–100) | 80 (60–105) | 60 (40–90.5) |
| ≤76* | 126 (50.8) | 105 (47.9) | 21 (72.4) |
| >76 | 122 (49.2) | 114 (52.1) | 8 (27.6) |
| Single versus multicentre study | |||
| Single centre | 230 (92.7) | 202 (92.2) | 28 (96.6) |
| Multicentre | 18 (7.3) | 17 (7.8) | 1 (3.4) |
| Length of follow-up | |||
| ≤4 weeks | 162 (65.3) | 153 (69.9) | 9 (31.0) |
| >4 weeks | 82 (33.1) | 64 (29.2) | 18 (62.1) |
| Unclear | 4 (1.60) | 2 (0.9) | 2 (6.9) |
| Scope of journals | |||
| Acupuncture-related | 58 (23.4) | 48 (21.9) | 10 (34.5) |
| Others (non-acupuncture) | 190 (76.6) | 171 (78.1) | 19 (65.5) |
| Sources of funding | |||
| Non-profit funding agencies | 62 (25.0) | 46 (21.0) | 16 (55.2) |
| Unclear | 186 (75.0) | 173 (79.0) | 13 (44.8) |
*Median.
RCT, randomised controlled trial.
Figure 2Risk of bias assessment of randomised controlled trials of acupuncture for knee osteoarthritis (n=248).
Randomisation and allocation concealment of included trials
| Items | Total | English | Chinese |
| Methods of randomisation sequence generated | |||
| Reported | 149 (60.1) | 17 (58.6) | 132 (60.3) |
| A random number table | 70 (47.0) | 4 (23.5) | 66 (50.0) |
| Computer-generated randomisation number | 39 (26.2) | 11 (64.7) | 28 (21.2) |
| Coin tossing | 2 (1.3) | 1 (5.9) | 1 (0.8) |
| Shuffling cards or envelopes | 2 (1.3) | 0 (0.0) | 2 (1.5) |
| Drawing of lots | 6 (4.1) | 0 (0.0) | 6 (4.5) |
| Visit order | 30 (20.1) | 1 (5.9) | 29 (22.0) |
| Unclear | 99 (39.9) | 12 (41.4) | 87 (39.7) |
| Methods of concealment of allocation | |||
| Reported | 31 (12.5) | 10 (35.5) | 21 (9.6) |
| Central allocation (telephone, web-based) | 1 (3.2) | 1 (10.0) | 0 (0.0) |
| Sequentially numbered, opaque, sealed envelopes | 30 (96.8) | 9 (90.0) | 21 (100.0) |
| Unclear | 217 (87.5) | 19 (65.5) | 198 (90.4) |
| Use of block randomisation | |||
| Yes | 15 (6.0) | 11 (37.9) | 4 (1.8) |
| Unclear | 233 (94.0) | 18 (62.1) | 215 (98.2) |
| Use of stratification at randomisation | |||
| Yes | 9 (3.6) | 4 (13.8) | 5 (2.3) |
| Unclear | 239 (96.4) | 25 (86.2) | 214 (97.7) |
Interventions and blinding of included trials
| Items | Total | English | Chinese |
| Type of the acupuncture of the experimental group | |||
| Filiform/ordinary needle | 107 (43.1) | 20 (69.0) | 87 (39.7) |
| Electro-acupuncture | 98 (39.5) | 4 (13.8) | 94 (42.9) |
| Fire needle | 14 (5.7) | 0 (0) | 14 (6.4) |
| Laser acupuncture | 4 (1.6) | 4 (13.8) | 0 (0.0) |
| Non-conventional acupuncture* | 20 (8.1) | 1 (3.4) | 19 (86.8) |
| Combination of different types of acupuncture | 5 (2.0) | 0 (0) | 5 (2.3) |
| The intervention of the control group | |||
| Multiple interventions† | 64 (25.8) | 2 (6.9) | 62 (28.3) |
| Acupuncture and moxibustion | 51 (20.6) | 2 (6.9) | 49 (22.4) |
| Pharmacological interventions | 45 (18.1) | 2 (6.9) | 43 (19.6) |
| Needle-knife | 29 (11.7) | 1 (3.4) | 28 (12.8) |
| Physical treatments | 22 (8.9) | 3 (10.3) | 19 (8.7) |
| Acupuncture | 21 (8.5) | 5 (17.2) | 16 (7.3) |
| Filiform needle | 9 (42.9) | 1 (3.4) | 8 (3.7) |
| Electro-acupuncture | 8 (38.1) | 1 (3.4) | 7 (3.2) |
| Fire needle | 4 (19.0) | 0 (0) | 4 (1.8) |
| Sham acupuncture | 8 (3.2) | 8 (27.6) | 0 (0) |
| Placebo acupuncture | 5 (2.0) | 5 (17.2) | 0 (0) |
| Moxibustion | 2 (0.8) | 0 (0) | 2 (0.9) |
| Waiting list | 1 (0.4) | 1 (3.4) | 0 (0) |
| Standardisation of the procedure | |||
| Acupuncture procedure was standardised | 25 (10.1) | 9 (31.0) | 16 (7.3) |
| Unclear | 223 (89.9) | 20 (69.0) | 203 (92.7) |
| How was the acupuncture procedure standardised? | |||
| Reported | 18 (7.3) | 8 (27.6) | 10 (4.6) |
| According to written manuals or specific guidelines | 11 (61.1) | 2 (25.0) | 9 (90.0) |
| Standardised acupuncture protocol | 7 (38.9) | 6 (75.0) | 1 (10.0) |
| Unclear | 230 (92.7) | 21 (72.4) | 209 (95.4) |
| Reasoning for the acupuncture procedure | |||
| Reported | 84 (33.9) | 13 (44.8) | 71 (32.4) |
| Theory | 60 (71.4) | 7 (53.8) | 53 (74.7) |
| Literature | 3 (3.6) | 2 (15.4) | 1 (1.4) |
| Consensus methods | 21 (25.0) | 4 (30.8) | 17 (23.9) |
| Unclear | 164 (66.1) | 16 (55.2) | 148 (67.6) |
| Who undertook acupuncture procedures? | |||
| Acupuncturist/doctor/physiotherapists | 18 (7.3) | 15 (51.7) | 3 (1.4) |
| Unclear | 230 (92.7) | 14 (48.3) | 216 (98.6) |
| Blinding | |||
| Any blinding | 233 (94.0) | 23 (79.3) | 210 (95.9) |
| Patient | |||
| Yes | 16 (6.9) | 14 (60.9) | 2 (1.0) |
| No | 11 (4.7) | 6 (26.12) | 5 (2.4) |
| Acupuncturist | |||
| Yes | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No | 21 (9.0) | 16 (69.6) | 5 (2.4) |
| Outcome assessor | |||
| Yes | 15 (6.4) | 12 (52.2) | 3 (1.4) |
| No | 5 (2.1) | 5 (21.7) | 0 (0.0) |
| Data analyst | |||
| Yes | 10 (4.3) | 7 (30.4) | 3 (1.4) |
| No | 5 (2.1) | 5 (21.7) | 0 (0.0) |
| Details not reported‡ | 204 (87.6) | 7 (30.4) | 197 (93.8) |
| Unclear | 15 (6.0) | 6 (20.7) | 9 (4.1) |
*Non-conventional acupuncture including silver needle, Fu’s subcutaneous, blade needle, longitudinal needle, ear needle and head needle.
†Multiple interventions including acupuncture or/and pharmacological or/and physical treatments in the control group.
‡Trials just stated as ‘single-blinded/double-blinded/blinded’ without giving further information.
Sample size calculation of included trial
| Items | Total | English | Chinese |
| Was sample size calculation conducted? | |||
| Reported | 17 (6.9) | 14 (48.3) | 3 (1.4) |
| Yes, details of the calculation reported | 17 (100.0) | 14 (100.0) | 3 (100.0) |
| Yes, but no statistical details | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| No | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Unclear | 231 (93.1) | 15 (51.7) | 216 (98.6) |
| Was the sample size calculated based on the defined primary outcome? | |||
| Reported | 17 (100.0) | 14 (100.0) | 3 (100.0) |
| Yes | 10 (58.8) | 9 (64.3) | 1 (33.3) |
| Unclear | 7 (41.2) | 5 (35.7·) | 2 (66.7) |
| Did the trial define α? | |||
| Reported | 17 (100.0) | 14 (100.0) | 3 (100.0) |
| Yes | 9 (52.9) | 9 (64.3) | 0 (0.0) |
| Unclear | 8 (47.1) | 5 (35.7) | 3 (100.0) |
| Did the trial define β? | |||
| Reported | 17 (100.0) | 14 (100.0) | 3 (100.0) |
| Yes | 12 (70.6) | 12 (85.7) | 0 (0.0) |
| Unclear | 5 (29.4) | 2 (14.3) | 3 (100.0) |
| What basis was the sample size calculated? | |||
| Reported | 11 (64.7) | 9 (64.3) | 2 (66.7) |
| Pilot study | 2 (18.2) | 2 (22.2) | 0 (0.0) |
| Previous study | 9 (81.8) | 7 (77.8) | 2 (100.0) |
| Unclear | 6 (35.3) | 5 (35.7) | 1 (33.3) |
| Was the loss to follow-up considered? | |||
| Reported | 11 (65.7) | 8 (57.1) | 3 (100) |
| Yes | 9 (81.8) | 6 (75.0) | 3 (100.0) |
| No | 2 (18.2) | 2 (25.0) | 0 (0.0) |
| Unclear | 6 (35.3) | 6 (42.9) | 0 (0.0) |
Primary outcome and data analyses of included trials
| Items | Total | English | Chinese |
| Specified primary outcome | |||
| Yes | 27 (10.9) | 11 (37.9) | 16 (7.3) |
| Unclear | 221 (89.1) | 18 (62.1) | 203 (92.7) |
| ITT principle used for primary outcome | |||
| Reported | 27 (100.0) | 11 (100.0) | 16 (100.0) |
| ITT analysis | 7 (25.9) | 5 (45.5) | 2 (12.5) |
| Not reported | 20 (74.1) | 6 (54.5) | 14 (87.5) |
| Type of the primary outcome(s) | |||
| Reported | 27 (100.0) | 11 (100.0) | 16 (100.0) |
| Patient-reported outcome | 25 (92.6) | 9 (81.8) | 16 (100.0) |
| Laboratory results | 1 (3.7) | 1 (9.1) | 0 (0.0) |
| Patient recruitment rate | 1 (3.7) | 1 (9.1) | 0 (0.0) |
| Did LTFU explicitly stated | |||
| Reported | 145 (58.5) | 27 (93.1) | 118 (53.9) |
| Yes, explicit statement: LTFU occurred | 46 (31.7) | 20 (74.1) | 26 (22.0) |
| Yes, explicit statement: LTFU did not occur | 99 (68.3) | 7 (25.9) | 92 (78.0) |
| No, no explicit statement about LTFU, unclear | 103 (41.5) | 2 (6.9) | 101 (46.1) |
| LTFU reported separately for the all arms | |||
| Reported | 46 (100.0) | 20 (100.0) | 26 (100.0) |
| Yes | 37 (80.4) | 18 (90.0) | 19 (73.1) |
| No | 9 (19.6) | 2 (10.0) | 7 (26.9) |
| Comparison of baseline characteristic of LTFU | |||
| Reported | 46 (100.0) | 20 (100.0) | 26 (100.0) |
| Yes | 1 (2.2) | 1 (5.0) | 0 (0.0) |
| No | 45 (97.8) | 19 (95.0) | 26 (100.0) |
| Analytical methods for LTFU data | |||
| Reported | 6 (13.1) | 6 (30.0) | 0 (0.0) |
| Last observation carried forward | 4 (66.6) | 4 (66.6) | 0 (0.0) |
| The worst of the scores obtained for the intervention group and the best obtained for the control group | 1 (16.7) | 1 (16.7) | 0 (0.0) |
| Baseline observation carried forward was used for missing data | 1 (16.7) | 1 (16.7) | 0 (0.0) |
| Unclear | 40 (86.9) | 14 (70.0) | 26 (100.0) |
ITT, intention to treat; LTFU, loss to follow-up.
Factors associated with methodological quality indicators
| Items | OR and 95% CI | |||
| Crude | P value | Adjusted* | P value* | |
| Randomisation sequence generated | ||||
| English vs Chinese (ref) | 1.39 (0.64 to 3.02) | 0.41 | 1.09 (0.45 to 2.62) | 0.85 |
| Multiple vs single centre (ref) | 1.78 (0.66 to 4.75) | 0.25 | 1.63 (0.57 to 4.67) | 0.37 |
| Funding vs unclear (ref) | 1.88 (1.05 to 3.37) | 0.04 | 1.75 (0.94 to 3.26) | 0.08 |
| Sample size>76 vs ≤76 (ref) | 0.75 (0.45 to 1.23) | 0.25 | 0.73 (0.43 to 1.22) | 0.23 |
| Allocation concealment | ||||
| English vs Chinese (ref) | 4.96 (2.04 to 12.08) | <0.01 | 4.99 (1.72 to 14.47) | <0.01 |
| Multiple vs single centre (ref) | 3.02 (0.99 to 9.17) | 0.05 | 4.49 (1.39 to 14.53) | 0.01 |
| Funding vs unclear (ref) | 1.79 (0.80 to 3.99) | 0.15 | 0.98 (0.36 to 2.62) | 0.97 |
| Sample size>76 vs ≤76 (ref) | 0.53 (0.24 to 1.15) | 0.11 | 0.55 (0.24 to 1.26) | 0.16 |
| Blinding of participants and personnel | ||||
| English vs Chinese (ref) | 203.47 (24.93 to 1660.49) | <0.01 | 230.74 (19.93 to 2671.65) | <0.01 |
| Multiple vs single centre (ref) | 0.91 (0.11 to 7.35) | 0.93 | 3.81 (0.59 to 24.46) | 0.16 |
| Funding vs unclear (ref) | 3.79 (1.31 to 10.95) | 0.01 | 0.90 (0.22 to 3.74) | 0.89 |
| Sample size>76 vs ≤76 (ref) | 0.35 (0.10 to 1.15) | 0.08 | 0.80 (0.16 to 3.89) | 0.78 |
| Blinding of outcome assessors | ||||
| English vs Chinese (ref) | 50.82 (13.03 to 198.18) | <0.01 | 199.82 (22.97 to 1738.10) | <0.01 |
| Multiple vs single centre (ref) | 3.63 (0.92 to 14.32) | 0.07 | 65.47 (6.03 to 710.78) | <0.01 |
| Funding vs unclear (ref) | 2.11 (0.72 to 6.19) | 0.18 | 0.29 (0.06 to 1.49) | 0.14 |
| Sample size>76 vs ≤76 (ref) | 0.24 (0.07 to 0.87) | 0.03 | 0.24 (0.04 to 1.40) | 0.11 |
*From separate logistic regression models adjusting for other factors.
ref, reference category.